Cyted Health Secures $44 Million to Expand Early Oesophageal Cancer Detection
Cambridge, UK – Cyted health, a medical technology company pioneering early detection of oesophageal disease, has announced a accomplished $44 million funding round. The investment will fuel the company’s expansion into the US market and broaden its diagnostic capabilities, addressing a critical need for earlier diagnosis of a frequently late-stage cancer.
Cyted Health’s innovative approach centers around a minimally invasive diagnostic test. Unlike traditional endoscopy, which can be uncomfortable and require significant readiness, cyted’s method involves swallowing a capsule containing a dissolvable sponge. This sponge collects cells as it travels through the oesophagus, providing a sample for analysis.The company’s EndoSign device has already received approval from the US Food and Drug Administration (FDA).
“about 80 per cent of oesophageal cancer cases in the UK are diagnosed too late for effective treatment,” explains Cyted Health. This highlights the urgent need for improved early detection methods. the new funding aims to address this gap by making Cyted’s technology more widely available.
The funding Breakdown
The funding round was led by EQT Life Sciences, with co-leadership from Advent Life Sciences and the British Business Bank. Existing investors Morningside and BGF also participated. The British Business Bank contributed £5 million to the round.
Here’s a table summarizing the key investors:
| Investor | Role | Investment (Approximate) |
|---|---|---|
| EQT Life Sciences | Lead Investor | Undisclosed |
| Advent Life Sciences | Co-Lead Investor | Undisclosed |
| British Business Bank | Co-Lead Investor | £5 million (approx. $6.25 million USD) |
| Morningside | Existing Investor | Undisclosed |
| BGF | Existing Investor | Undisclosed |
The company plans to use the funds to:
Expand US commercialization: Accelerate the rollout of its diagnostics platform across the united States.
Strengthen UK Presence: Consolidate its existing commercial success within the UK market.
* Develop New Tests: Expand its portfolio of advanced diagnostic tests for oesophageal conditions.
Government Support and the Importance of Life Sciences
The UK government has expressed strong support for Cyted Health’s work. Lord Vallance of balham, the science minister, stated that the company’s growth “demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities.” He further emphasized the critical role of life sciences in the government’s economic and healthcare ambitions.
The increasing focus on early cancer detection is driven by the understanding that earlier diagnosis leads to more effective treatment options and improved survival rates. Cyted Health’s innovative technology represents a promising step towards achieving this goal for oesophageal cancer patients.